Your browser is no longer supported. Please, upgrade your browser.
Renalytix AI plc
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand34.92M Perf Week46.36%
Market Cap860.66M Forward P/E- EPS next Y- Insider Trans- Shs Float5.50M Perf Month77.57%
Income- PEG- EPS next Q- Inst Own13.60% Short Float1.76% Perf Quarter97.52%
Sales- P/S- EPS this Y72.30% Inst Trans- Short Ratio1.45 Perf Half Y65.33%
Book/sh2.55 P/B8.75 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh2.13 P/C10.46 EPS next 5Y- ROE- 52W Range9.91 - 22.48 Perf YTD39.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-0.71% Beta-
Dividend %- Quick Ratio22.70 Sales past 5Y- Gross Margin- 52W Low125.30% ATR1.60
Employees17 Current Ratio22.70 Sales Q/Q- Oper. Margin- RSI (14)80.19 Volatility15.61% 9.78%
OptionableNo Debt/Eq0.02 EPS Q/Q81.90% Profit Margin- Rel Volume1.88 Prev Close22.32
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume66.71K Price22.32
Recom- SMA2044.66% SMA5064.82% SMA20064.18% Volume125,722 Change0.00%
Aug-11-20Initiated Stifel Buy
Jan-13-21 02:00AM  
Jan-06-21 08:54AM  
Jan-05-21 06:00AM  
Jan-04-21 08:05AM  
Nov-29-20 11:42AM  
Nov-25-20 07:30AM  
Nov-13-20 02:00AM  
Nov-06-20 07:00AM  
Nov-02-20 10:30AM  
Oct-28-20 07:30AM  
Oct-27-20 03:00AM  
Oct-26-20 07:30AM  
Sep-22-20 07:00AM  
Sep-18-20 07:00AM  
Aug-26-20 07:00AM  
Aug-21-20 03:00AM  
Aug-03-20 08:00AM  
Jul-27-20 08:00AM  
Jul-21-20 03:57PM  
Jul-16-20 11:38PM  
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.